Data was collected from patients undergoing RP at the Ochsner Clinic. Biopsy tissue was analyzed for the RNA expression of 31 cell cycle progression (CCP) genes and 15 housekeeping genes in order to obtain a CCP score. Cancer of the Prostate Risk Assessment (CAPRA) scores were also determined based on clinicopathologic features at the time of diagnosis. Clinical and molecular measures of disease aggressiveness were compared based on ancestry. A total of 384 patients were treated with RP, including 133 (34. 8%) men of AA ancestry.
The median age at diagnosis was 62 years (interquartile range (IQR) 56, 66) and PSA was 5. 4 ng/mL (IQR 4. 2, 7. 6). Stratified by ancestry, there were no significant differences in biopsy Gleason score (p=0. 26), clinical stage (p=0. 27), CAPRA score (p=0. 58), or CCP score (p=0. 87). In addition, there was no significant difference in the risk of biochemical recurrence between ancestries (p=0. 55).
In conclusion, these data suggested men of AA ancestry do not necessarily present with or develop a more biologically aggressive form of prostate cancer. Although these data represent only one institution’s experience, it contains a highly robust African American population, indicating the need for further research to understand these disparities.
Presented By: Daniel J. Canter, MD, Ochsner Clinic, New Orleans, Louisiana
Written by: Stephen B. Williams, MD., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, MD. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 2018 American College of Surgeons Clinical Congress, October 21-25, 2018 in Boston, Massachusetts